Journals / İstanbul Tıp Dergisi / 2011 / Cilt: 12 - Sayı: 1

Demographic and clinical properties and medical treatments of patients followed as ankylosing spondylitis

Ankilozan spondilitli hastalara ait demografik veriler, klinik özellikler ve medikal tedavileri

Pages
19–24
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The BASDAI as showing disease activity was correlated with peripherical involvement, enthesopathy, VAS, duration of disease, delay time in diagnose, ESR and CRP values.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim is to assess the clinical and demographic properties of the patients followed as ankylosing spondylitis (AS).
📊
Key Findings & Data:Methods: We evaluated 243 patients’ folders retrospectively which were diagnosed and followed up as AS between 2007- 2008 years.
💡
Conclusion & Impact:The BASDAI as showing disease activity was correlated with peripherical involvement, enthesopathy, VAS, duration of disease, delay time in diagnose, ESR and CRP values.
🔬Design:Survey & Empirical Study
📍Scope:2007- 2008 Verileri
⚙️Variables:Domain Parameters

Abstract

The aim is to assess the clinical and demographic properties of the patients followed as ankylosing spondylitis (AS). Methods: We evaluated 243 patients’ folders retrospectively which were diagnosed and followed up as AS between 2007- 2008 years. Demographical properties, follow-up parameters and treatments were assessed. Visual Analog Scale (VAS), Bath AS Disease Activity Index (BASDAI), Bath AS Funxional Index (BASFI), Bath AS Metrologıcal Index (BASMI), Bath AS Radiological Index (BASRI), AS Questionnaire of Life (ASQOL), Maastricht Score of Entesopathy (MASES), Eritrocyte Sedimentation Rate (ESR), C-reactive protein (CRP) were analyzed. Results: Male to female ratio was 3,4: 1. Means of age, age at the diagnose, delay time in diagnose were respectively 37.1±9 years, 32.4±9 years and 4.6±6 years. The mean values were respectively BASMI 7.9±2.5, BASFI 3.4±2.6, ASQOL 9.2±5.9, BASRI 6.7±2.8, VAS 45.9±28.2, entesopathy score 2.5±3.8, ESR 24.9 mm/hr, CRP 1.5±1.8 mg/dl. The 54.3% of the patients’ BASDAI scores were under 4 but near 4 with mean of 3.9±2.3. 12.8% had uveitis, 15,6% had peripherical involvement. The 3.8% had no treatment, 16.8% had only Non Steroid Anti Inflamatary Drugs (NSAID), 65.4% had monotheraphy, 6.6% had two Modifying Anti-rheumatic Drugs (DMARD) and 7.4% had biological agents as treatment protocols. 61.3% of the monotheraphy group were using sulfasalazine. Conclusion: There was no statistically significant difference in means of ages and diagnose ages between gender but delay time in diagnose was longer in women. BASRI scores were higher in men significantly. Also peripherical involvement and CRP values were higher in men. The BASDAI as showing disease activity was correlated with peripherical involvement, enthesopathy, VAS, duration of disease, delay time in diagnose, ESR and CRP values.

Özet

Ankilozan spondilit (AS) tanısı ile takip edilen hastalara ait demografik veriler, klinik özellikler ve medikal tedaviler değerlendirildi. Gereç ve Yöntem: 2007-2008 tarihleri arasında AS tanısı ile takip edilen 243 hastanın dosyası retrospektif olarak incelendi. Hastaların demografik özellikleri, hastalık takip parametreleri ve mevcut tedavileri değerlendirildi. Hastalık takibinde kullanılan Görsel Analog Skala (VAS), Bath AS Hastalık Aktivite İndeksi (BASDAI), Bath AS Fonksiyonel İndeksi (BASFI), Bath AS Metrolojik İndeksi (BASMI), Bath AS Radyolojik İndeksi (BASRI), AS Yaşam Kalitesi Anketi (ASQOL), Maastricht Entesopati Skoru (MASES), eritrosit sedimentasyon hızı (ESR), C-reaktif protein (CRP) değerleri incelendi. Bulgular: Erkek/kadın 3,4:1 idi. Yaş ortalaması, tanı yaşı ve tanıdaki gecikme süreleri sırasıyla, 37,1±9, 32,4±9 ve 4,6±6 yıl idi. Takip parametrelerimizin ortalama değerleri sırasıyla BASMI 7,9±2,5, BASFI 3,4±2,6, ASQOL 9,2±5,9, BASRI 6,7±2,8, VAS 45,9±28,2, entesopati skoru 2,5±3,8, ESR 24,9 mm/st, CRP 1,5±1,8 mg/dl idi. Hastaların %54,3’nün BASDAI skorları 4’ün altında olup ortalama 3,9±2,3 ile 4’e yakındı. Hastaların %12,8’inde üveit, %15,6’sında periferik artrit vardı. Hastaların %3,8’i hiçbir tedavi almıyor, %16,8’i sadece nonsteroid antienflamatuvar ilaç, %65,4’ü tekli modifiye edici anti romatizmal ilaç (DMARD), %6,6’sı ikili DMARD, %7,4’ü biyolojik ajan kullanıyordu. Tekli DMARD grubunun %61,3’ü sulfasalazin kullanıyordu. Sonuç: Cinsiyetler karşılaştırıldığında yaş ortalaması ve tanı yaşı açısından anlamlı fark olmazken, tanının gecikme süresi kadınlarda istatistiksel olarak anlamlı derecede fazlaydı. BASRI skorları erkeklerde yüksekti. Periferik artrit ve CRP değerleri erkeklerde daha fazla yoktu. Hastalık aktivitesini gösteren BASDAI yüksekliği ile periferik tutulum, entesopati, VAS, hastalık süresi, tanıda gecikme süresi, ESR ve CRP değerleri arasında anlamlı ilişki saptandı.

🔖

Cite This Article

ÖZGÖNENEL, L., AYTEKİN, E., BURNAZ, Ö., TÜTÜN, Ş., ÇETİN, E., AKIN, T., ÇAĞLAR, S. N., ÖRNEK, T. G., ŞENER, O. (2022). Demographic and clinical properties and medical treatments of patients followed as ankylosing spondylitis. İstanbul Tıp Dergisi, Cilt: 12 - Sayı: 1, 19–24. https://ajindex.com/articles/552572

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Van der Linden S, Vonder Heide D, Braun J. Ankylosing spondylitis. In: Harris ED, editor. Kelley’s textbook of rheumatology. 7th ed. 2006. p. 1125-38. Çalgüneri M. Ankilozan spondilit. İmmünoloji- Romatoloji Dergisi 2004:4(1). Altan L. Ankilozan spondilitte güncel tedavi seçenekleri. Türk Fiz Tıp Rehab Derg 2005;51(özel Ek A):A33-A39. Van der Linden S, Valkenburg HA, Cats A: Evaluation of Diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
  2. Dernis E, Lavie F, Pauy S, et al. Clinical and laboratory follow-up for treating and monitoring patients with anklosing spondylitis: development of recommendations for clinical practice based on published evidence and export opinion. Joint Bone Spine 2007;74:330-7.
  3. Bodur H, Ataman S, Akbulut L, et al. Characteristics and medical management of patients with rheumatoid arthritis and ankylosing spondylitis. Clin Rheumatol 2008;27:1119-25.
  4. Rudwaleit M, Van der Heijde, Khan MA, et al. How to diagnose axlal spondyloarthritis early. Ann Rheum Dis 2004;63:535-43.
  5. Sieper J, Braun J. Clinician’s manual on ankylosing spondylitis. London: Current Medicine Group. Dejaco C, Duftner C, Schirmer M. Imaging techniques for early diagnosis of ankylosing spondylitis. Wien Med Wochenschr 2008;158:191-4.
  6. Lee W, Reveille JD, Davis JC, et al. Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort. Ann Rheum Dis 2007;66:633-8. Sivrioğlu K. Ankilozan spondilitte sınıflama, etiyopatogenez ve değerlendirme. Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi 2005;51(Özel Ek B):44-50.
  7. Karan A, Özcan E, Aydın R ve ark. Ankilozan spondilitli hastaları değerlendirmede kullanılanskalaların karşılaştırılması. Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi 1999:2:18-22.
  8. Lavie F, Pavy S, Dernis E, et al. Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion. Joint Bone Spine 2007;74:346-52.
  9. Pedersen SJ, Sorensen IJ, Hermann KG, et al. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow up study of patients with axial spondylarthritis treated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 2010;69:1065-71.
  10. Baskan BM, Sivas F, Inal EE, et al. Comparison of the Bath Ankylosing Spondylitis Radiology Index and the Modified Stoke